Computational discovery of potential therapeutic agents against brain-eating amoeba (Naegleria fowleri)

Jacopo Zattoni1, Richard F Ludueña2, Maral Aminpour1

  • 1Department of Biomedical Engineering, University of Alberta, Donadeo Innovation Centre for Engineering, Edmonton, Alberta, Canada.

Plos One
|July 11, 2025
PubMed

Insights

Naegleria fowleri infections are deadly, but tubulin-targeting drugs show promise. Bioinformatics analysis identified the Colchicine binding site as a potential target for developing new treatments against this brain-eating amoeba.

Area of Science:

  • Parasitology
  • Computational Biology
  • Drug Discovery

Background:

  • Naegleria fowleri causes Primary Amoebic Meningoencephalitis, a rare but nearly fatal brain infection.
  • Current treatments are ineffective due to non-specific symptoms and lack of targeted therapies.

Purpose of the Study:

  • To explore the potential of tubulin-targeting compounds for treating Naegleria fowleri infections.
  • To analyze differences in amoeba and human tubulins for drug resistance insights.

Main Methods:

  • Bioinformatics analysis of Naegleria fowleri tubulin sequences.
  • Molecular docking simulations to assess binding affinity of compounds to amoeba and human tubulins.
  • Consensus analysis of docking results for reliability.

Main Results:

  • Significant sequence changes in amoeba mitotic tubulins may affect drug binding.
  • The Colchicine binding site was identified as a promising target.
  • Colchicine analogs show potential for binding to amoeba tubulins, but selectivity remains a challenge.

Conclusions:

  • Structural modifications in the Colchicine binding site offer a basis for designing more selective and safer anti-Naegleria drugs.
  • This research provides a foundation for developing novel therapeutic agents against Naegleria fowleri infections.